Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers

被引:11
|
作者
Azzarouali, Sana [1 ,2 ,3 ]
Goudschaal, Karin [2 ,3 ]
Visser, Jorrit [2 ,3 ]
Hulshof, Maarten [2 ,3 ]
Admiraal, Marjan [1 ,2 ]
van Wieringen, Niek [2 ,3 ]
Nieuwenhuijzen, Jakko [2 ,4 ]
Wiersma, Jan [2 ,3 ]
Daniels, Laurien [2 ,3 ]
den Boer, Duncan [1 ,2 ]
Bel, Arjan [2 ,3 ]
机构
[1] Vrije Univ Amsterdam, Radiat Oncol, Amsterdam UMC locat, Amsterdam, Netherlands
[2] Canc Ctr Amsterdam, Canc Therapy Treatment & qual life, Amsterdam, Netherlands
[3] Univ Amsterdam, Radiat Oncol, Amsterdam UMC locat, Meibergdreef 9, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam, Amsterdam UMC locat, De Boelelaan 1117, Amsterdam, Netherlands
关键词
Online adaptive radiotherapy; Bladder cancer; Fiducial markers; Reoptimization; Artificial intelligence; Radiotherapy; CBCT; Focal boost; Cone Beam CT; RADIATION-THERAPY; RADICAL CYSTECTOMY; GUIDED RADIOTHERAPY; SELECTION; VOLUME; VARIABILITY; OUTCOMES; MOTION; TUMOR;
D O I
10.1186/s13014-023-02348-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe aim was to assess the feasibility of online adaptive radiotherapy (oART) for bladder cancer using a focal boost by focusing on the quality of the online treatment plan and automatic target delineation, duration of the workflow and performance in the presence of fiducial markers for tumor bed localization.MethodsFifteen patients with muscle invasive bladder cancer received daily oART with Cone Beam CT (CBCT), artificial intelligence (AI)-assisted automatic delineation of the daily anatomy and online plan reoptimization. The bladder and pelvic lymph nodes received a total dose of 40 Gy in 20 fractions, the tumor received an additional simultaneously integrated boost (SIB) of 15 Gy. The dose distribution of the reference plan was calculated for the daily anatomy, i.e. the scheduled plan. Simultaneously, a reoptimization of the plan was performed i.e. the adaptive plan. The target coverage and V95% outside the target were evaluated for both plans. The need for manual adjustments of the GTV delineation, the duration of the workflow and the influence of fiducial markers were assessed.ResultsAll 300 adaptive plans met the requirement of the CTV-coverage V95%>= 98% for both the boost (55 Gy) and elective volume (40 Gy). For the scheduled plans the CTV-coverage was 53.5% and 98.5%, respectively. Significantly less tissue outside the targets received 55 Gy in case of the adaptive plans as compared to the scheduled plans. Manual corrections of the GTV were performed in 67% of the sessions. In 96% of these corrections the GTV was enlarged and resulted in a median improvement of 1% for the target coverage. The median on-couch time was 22 min. A third of the session time consisted of reoptimization of the treatment plan. Fiducial markers were visible on the CBCTs and aided the tumor localization.ConclusionsAI-driven CBCT-guided oART aided by fiducial markers is feasible for bladder cancer radiotherapy treatment including a SIB. The quality of the adaptive plans met the clinical requirements and fiducial markers were visible enabling consistent daily tumor localization. Improved automatic delineation to lower the need for manual corrections and faster reoptimization would result in shorter session time.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Benefits of bespoke PTV margins for bladder cancer using CBCT-guided online adaptive radiotherapy
    Bolt, M.
    Shelley, C.
    Hollingdale, R.
    Goh, C.
    Adams, E.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S730 - S731
  • [42] Ultra-hypofractionated breast radiotherapy & simultaneous integrated boost for early breast cancer
    Montero, A.
    Canadillas, C.
    Ciervide, R.
    Garcia-Aranda, M.
    Alvarez, B.
    Prado, A.
    Chen-Zhao, X.
    Valero, J.
    Lopez, M.
    Alonso, R.
    Hernando, O.
    Sanchez, E.
    Garcia, J.
    Rossi, K.
    Izquierdo, M.
    Fernandez-Leton, P.
    Rubio, C.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1019 - S1020
  • [43] Simultaneous integrated boost in short-course radiotherapy; a novel approach for rectal cancer
    Vieira, S.
    Pares, O.
    Stroom, J.
    Greco, C.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S182 - S183
  • [44] The impact of image guided radiotherapy in the primary treatment of prostate cancer with a simultaneous integrated boost
    Duma, M. N.
    Petrucci, A.
    Molls, M.
    Geinitz, H.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (09) : 598 - 598
  • [45] Long-term outcomes of radical radiotherapy with a simultaneous integrated boost in esophageal cancer
    Luo, T.
    Chen, J.
    Guo, H.
    Zhai, T.
    Huang, R.
    Chen, Z.
    Lin, K.
    Zeng, C.
    Liu, W.
    Zhou, M.
    Li, D.
    Li, D.
    Chen, C.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S175 - S175
  • [46] Simultaneous integrated intensity modulated radiotherapy boost for gynecological cancer when brachytherapy is not an option
    Kucuktulul, Eda
    Yurekli, Ahmet Fatih
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2020, 41 (05) : 720 - 725
  • [47] Simultaneous Integrated Boost: Improving the Patient Journey During Breast Cancer Radiotherapy Safely
    Chatterjee, S.
    Mahata, A.
    Mandal, S.
    Chakraborty, S.
    CLINICAL ONCOLOGY, 2019, 31 (04) : 266 - 266
  • [48] Adaptation Time as a Determinant of the Dosimetric Effectiveness of Online Adaptive Radiotherapy for Bladder Cancer
    Khouya, Aymane
    Poettgen, Christoph
    Hoffmann, Christian
    Ringbaek, Toke Printz
    Luebcke, Wolfgang
    Indenkaempen, Frank
    Guberina, Maja
    Guberina, Nika
    Gauler, Thomas
    Stuschke, Martin
    Garcia, Alina Santiago
    CANCERS, 2023, 15 (23)
  • [49] Online adaptive image guided radiotherapy for muscle-invasive bladder cancer
    Foroudi, F.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S241 - S241
  • [50] The potential of MRI-guided online adaptive radiotherapy of urinary bladder cancer
    Vestergaard, A.
    Hafeez, S.
    Muren, L. P.
    Nill, S.
    Hoyer, M.
    Hansen, V. N.
    Gronborg, C.
    Pedersen, E. M.
    Petersen, J. B. B.
    Huddart, R.
    Olfke, U.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S194 - S194